Meeting NewsVideo

VIDEO: Ipsen presentations spotlight cabozantinib’s potential in hepatocellular carcinoma, gastrointestinal stromal tumor

CHICAGO — Alexandre Lebeaut, MD, head of research and development at Ipsen Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and promising investigational agents in its pipeline.

ASCO presentations spotlighted data from trials that evaluated cabozantinib (Cabometyx) for patients with advanced hepatocellular carcinoma or metastatic gastrointestinal stromal tumor. Other abstracts focused on use of liposomal irinotecan injection for patients with small cell lung cancer, and the use of lanreotide autogel for treatment of clinical symptoms associated with inoperable malignant intestinal obstruction.

CHICAGO — Alexandre Lebeaut, MD, head of research and development at Ipsen Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and promising investigational agents in its pipeline.

ASCO presentations spotlighted data from trials that evaluated cabozantinib (Cabometyx) for patients with advanced hepatocellular carcinoma or metastatic gastrointestinal stromal tumor. Other abstracts focused on use of liposomal irinotecan injection for patients with small cell lung cancer, and the use of lanreotide autogel for treatment of clinical symptoms associated with inoperable malignant intestinal obstruction.

    See more from ASCO Annual Meeting